Stock screener

ENTX

Conviction 92HealthcareScan · Tue, Sep 8, 2026
ENTX$3.01+0.33%
ResistanceSupportVol 14
63 bars
Vol MA14 405.99K
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Entera Bio Ltd.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.enterabio.com ↗
Price3.01
Change+0.33%
Gap-3.00%
Rel volume3.05×
Avg volume383.72K
Avg $ vol1.17M
SMA 203.04
SMA 502.57
SMA 2001.75
Price vs 50+16.95%
Price vs 200+71.99%
MA stackbullish
50/200 cross—
Supertrendup · 2.69
RSI (14)54
MACD hist-0.06
MACD crossbear · 8d
Stoch %K / %D28 / 25
ADX (14)38
+DI / −DI22 / 16
RSI divergence—
MACD divergence—
ATR %+8.33%
ADR %7.63%
52w high3.92
52w low1.00
From 52w high-23.21%
Above 52w low+201.00%
New 52w highNo
SqueezeOff
Bollinger width23.38%
%B0.46
Donchian pos32.12%
Donchian high3.56
Donchian low2.75
AVWAP (52w high)3.53
vs AVWAP high-14.66%
AVWAP (52w low)2.82
vs AVWAP low+6.82%
OBV trendUp
Chaikin MF (20)0.08
Today vs 20d3.05×
Avg vol (14d)405.99K
Avg vol (20d)383.72K
Avg $ vol (20d)1.17M
Market cap521.16M
RS 3m (vs SPY)+149.81%
RS 6m (vs SPY)+125.45%
RS line new highNo
Trend template6/8
Technical rank85.7
1 week+2.03%
1 month+4.88%
3 months+150.83%
6 months+126.32%
1 year+46.12%
YTD+70.06%
P/E-45.56
P/B71.73
P/S—
P/FCF-69.70
EPS0.2500
Div yield—
ROE-157.43%
ROA-58.72%
Debt/Eq—
Current8.98
EV/EBITDA—
Gross margin0.00%
Net margin—
Rev growth-76.80%
EPS growth-19.89%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value509.85M
Revenue0
Net income-7.31M
Gross profit0
Free cash flow-7.48M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out49.29M
Employees22
ListedThu, Jun 28, 2018
Free float25.65M
Float %55.0%
Short interest956.76K
Days to cover1.9d
Short volume75.3%
Squeeze score52 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeA+
Conviction92 / 100
Pattern quality—
Tech rank85.7 / 100
Group rank96 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.88
Support2.66
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ENTX

All disclosures →
No recent disclosed trades by Congress in ENTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ENTX · 10 buys

InsiderSideShares
Ellis Sean
Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07
Grant20.03K
Ellis Sean
Director · Stock Option (right to buy) · 2026-08-07
Grant40K
Burshtein Gregory
Chief of R&D · Stock Option (right to buy) · 2026-08-07
Grant180K
Germano Geno J
Director · Ordinary Shares, par value NIS 0.0000769 per share · 2026-08-07
Grant25.01K
Germano Geno J
Director · Stock Option (right to buy) · 2026-08-07
Grant50K
Germano Geno J
Director · Stock Option (right to buy) · 2026-08-07
Grant43.01K
Toledano Miranda Jayne
Chief Executive Officer · Stock Option (right to buy) · 2026-08-07
Grant500K
Toledano Miranda Jayne
Chief Executive Officer · Stock Option (right to buy) · 2026-08-07
Grant200K
Galitzer Hillel
Chief Operating Officer · Stock Option (right to buy) · 2026-08-07
Grant200K
Yaacov-Garbeli Dana
Chief Financial Officer · Stock Option (right to buy) · 2026-08-07
Grant140K

SEC filings

EDGAR filings in ENTX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.